Cazelles, R; Shukla, RP; Ware, RE; Vinks, AA; Ben-Yoav, H.
Electrochemical Determination of Hydroxyurea in a Complex Biological Matrix Using MoS2-Modified Electrodes and Chemometrics.
Biomedicines.
2021;
9.
Dong, M; McGann, PT.
Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine.
Clinical Pharmacology and Therapeutics.
2021;
109:73-81.
Girdwood, ST; Kaplan, J; Vinks, AA.
Methodologic Progress Note: Opportunistic Sampling for Pharmacology Studies in Hospitalized Children.
Journal of hospital medicine (Online).
2021;
16:35-37.
McPhail, BT; Emoto, C; Butler, D; Fukuda, T; Akinbi, H; Vinks, AA.
Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches.
Journal of Clinical Pharmacology.
2021.
Mizuno, T; McPhail, BT; Kamatkar, S; Wexelblatt, S; Ward, L; Christians, U; Akinbi, HT; Vinks, AA.
Physiologic Indirect Response Modeling to Describe Buprenorphine Pharmacodynamics in Newborns Treated for Neonatal Opioid Withdrawal Syndrome.
Clinical Pharmacokinetics.
2021;
60:249-259.
Neely, MN; Vinks, AA.
Roger W. Jelliffe, MD, FCP, FAAPS: A World Leader in Population Pharmacokinetic and Pharmacodynamic Modeling and Model-Based Target Controlled Individualized Dosing.
Clinical Pharmacology and Therapeutics.
2021;
109:22-24.
Peck, RW; Shahin, MH; Vinks, AA.
Precision Dosing: The Clinical Pharmacology of Goldilocks.
Clinical Pharmacology and Therapeutics.
2021;
109:11-14.
Sebold, AJ; Day, AM; Ewen, J; Adamek, J; Byars, A; Cohen, B; Kossoff, EH; Mizuno, T; Ryan, M; Sievers, J; et al.
Sirolimus Treatment in Sturge-Weber Syndrome.
Pediatric Neurology.
2021;
115:29-40.
Soul, JS; Bergin, AM; Stopp, C; Hayes, B; Singh, A; Fortuno, CR; O'Reilly, D; Krishnamoorthy, K; Jensen, FE; Rofeberg, V; et al.
A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures.
Annals of Neurology.
2021;
89:327-340.
van Hoogdalem, MW; McPhail, BT; Hahn, D; Wexelblatt, SL; Akinbi, HT; Vinks, AA; Mizuno, T.
Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamics.
Expert Opinion on Drug Metabolism and Toxicology.
2021;
17:87-103.
Weiss, BD; Wolters, PL; Plotkin, SR; Widemann, BC; Tonsgard, JH; Blakeley, J; Allen, JC; Schorry, E; Korf, B; Robison, NJ; et al.
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
Journal of Clinical Oncology.
2021;
39:797-806.
Wright, KD; Yao, X; London, WB; Kao, PC; Gore, L; Hunger, S; Geyer, R; Cohen, KJ; Allen, JC; Katzenstein, HM; et al.
A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma.
Pediatric Blood and Cancer.
2021;
68.
Xiong, Y; Mizuno, T; Colman, R; Hyams, J; Noe, JD; Boyle, B; Tsai, YT; Dong, M; Jackson, K; Punt, N; et al.
Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease.
Clinical Pharmacology and Therapeutics.
2021.
Yi, JS; Perla, S; Huang, Y; Mizuno, K; Giordano, FJ; Vinks, AA; Bennett, AM.
Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines.
Cardiovascular Drugs and Therapy.
2021.
Zhao, J; Sharat, C; Mehta, PA; Mizuno, K; Vinks, AA; Setchell, KD R.
Paperspray Ionization Mass Spectrometry as a Tool for Predicting Real-Time Optimized Dosing of the Chemotherapeutic Drug Melphalan.
Journal of Applied Laboratory Medicine.
2021.